Connect with us

Technology

Ultrasound Market to be Worth $18.07 billion by 2031 – Exclusive Report by Meticulous Research®

Published

on

REDDING, Calif., Aug. 21, 2024 /PRNewswire/ — According to a new market research report, ‘Ultrasound Market Size, Share, Forecast, & Trends Analysis by Component (Device, Probe) Technology (3D, Doppler) Display (Color, B/W) Portability (Cart, Handheld, POC), Application (Cardiology, Therapeutic, Vascular) End User—Global Forecast to 2031,’ published by Meticulous Research®, the ultrasound market is projected to reach $18.07 billion by 2031, at a CAGR of 5.8% from 2024 to 2031.

Download Sample Report Now – https://www.meticulousresearch.com/download-sample-report/cp_id=4972

The report offers a competitive landscape based on an extensive assessment of product offerings, geographical presence, and key growth strategies adopted by prominent market players over the past three to four years. The key players profiled in the ultrasound market study are GE Healthcare Technologies Inc. (U.S.), Konica Minolta, Inc. (Japan), Koninklijke Philips N.V. (Netherlands), Siemens Healthineers AG (Germany), Canon Inc. (Japan), Esaote S.p.A (Italy), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Samsung Medison Co., Ltd. (South Korea), FUJIFILM SonoSite, Inc. (A Subsidiary of FUJIFILM Holdings Corporation) (U.S.), and Hologic, Inc. (U.S.).

The growth of the ultrasound market is driven by the aging population with chronic disorders, advancements in ultrasound device technology, the rising number of diagnostic imaging centers and hospitals, the rising incidence of orthopedic injuries and musculoskeletal disorders, and the increasing public & private investments, funding, and grants for ultrasound device development. However, stringent government regulations for trading, manufacturing, distribution, and sales of ultrasound imaging products restrain the market’s growth.

Furthermore, the emergence of point-of-care ultrasound devices and the demand from emerging economies are expected to create market growth opportunities.

Technological Advancements in Ultrasound Devices

In earlier years, medical imaging primarily served as a diagnostic tool. However, due to technological advancements, it now plays a crucial role in treating, managing, and predicting diseases. Medical imaging has become indispensable for diagnosing and treating major medical conditions like cancer, cardiovascular disease, musculoskeletal issues, urological conditions, and more. Among these, ultrasound machines have gained widespread use in diagnostic medical imaging due to their safety compared to X-ray machines. Technological improvements in ultrasound machines have revolutionized patient care, enhanced diagnostic accuracy, and benefited individuals with chronic conditions.

Get a Glimpse Inside: Request Sample Pages- https://www.meticulousresearch.com/request-sample-report/cp_id=4972

Ultrasound machines are becoming increasingly portable, lightweight, and compact. The integration of dual-probe technology, which combines two transducers into a single probe, has resulted in more accurate, dependable results, offering high-quality imaging and swift diagnostics at an affordable cost. These advancements empower medical professionals to view internal body structures and organs directly on smartphones.

3D/4D ultrasound has gained significant traction in maternity and obstetric scanning and is increasingly used for procedural planning and guidance. 3D imaging technology equips clinicians with clearer anatomical images, enhancing interventions and surgical planning. For instance, Philips TrueVue and GlassVue are advanced 3D ultrasound display methods that provide an early and photorealistic fetal image. 

Furthermore, ultrasound machines have streamlined workflows through features like auto-image optimization, scan assistance, and automation of measurements. These enhancements bolster productivity and efficiency while reducing repetitive tasks, enabling less experienced physicians to conduct scans without the need for radiologists. As a result, these technical strides continue to drive the demand for ultrasound devices across various medical applications.

The ultrasound market is segmented by component [{ultrasound devices, transducers/probes, gels, and other components}, technology {diagnostic ultrasound (2D ultrasound, 3D and 4D ultrasound, doppler ultrasound (color doppler imaging, continuous doppler imaging, pulse wave doppler imaging), therapeutic ultrasound (high-intensity focused ultrasound, lithotripsy (extracorporeal shock wave lithotripsy, shock wave lithotripsy)}, display {colored display, black and white display}, portability {cart/trolley based ultrasound systems, handheld/compact ultrasound systems, point of care ultrasound systems}, applications {diagnostic applications (general imaging, cardiology, obstetrics/gynecology, vascular, urology, and other diagnostic applications), therapeutic applications (drug delivery, physical therapy, pain management, and other therapeutic applications)}, end user {hospitals and clinics, diagnostics imaging centers, ambulatory care centers, and academic and research institutes}], and geography. The study also evaluates industry competitors and analyzes their market share at the regional and country levels.

Have Specific Research Needs? Request a Customized Report- https://www.meticulousresearch.com/request-customization/cp_id=4972

Among the components studied in the report, in 2024, the ultrasound devices segment is expected to account for the largest share of the ultrasound market. The large market share of this segment is attributed to the growing prevalence of musculoskeletal and orthopedic injuries. Additionally, the high demand for handheld ultrasound devices due to their benefits, such as enhanced patient throughput, heightened patient engagement, simplified operation, and increased convenience, contribute to the significant market share of this segment.

Among the technologies studied in the report, in 2024, the diagnostic ultrasound segment is expected to account for the largest share of the ultrasound market. Clinicians prefer diagnostic ultrasound due to its inherent benefits, including safety, effectiveness, non-invasiveness, high flexibility as an imaging modality, dynamic and precise imaging capabilities, and its cost-effectiveness compared to alternative imaging methods.

Among the displays studied in the report, in 2024, the colored display segment is expected to account for the largest share of the ultrasound market. The significant share of this segment is attributed to the advantages of colored displays, including enhanced visualization of ultrasound images, minimizing the need for invasive procedures. These displays enable non-invasive imaging of internal structures, facilitating swift diagnosis and treatment while offering cost-effectiveness and mitigating risks associated with more invasive procedures.

Among the portability modes studied in the report, in 2024, the cart-based trolley ultrasound devices segment is expected to account for the largest share of the ultrasound market. The large market share of the segment is attributed to the accessibility and portability offered by these devices, making them adaptable for use wherever patients are situated. They offer enhanced versatility, safety, and non-invasiveness alongside user-friendliness, resulting in widespread adoption in healthcare facilities.

Among the applications studied in the report, in 2024, the diagnostic applications segment is expected to account for the largest share of 65% of the ultrasound market. Technological advances in modalities for specialized applications, the rising prevalence of chronic diseases, and increasing awareness among people regarding early diagnosis contribute to the significant market share of this segment.

Among the end users studied in the report, in 2024, the hospitals & clinics segment is expected to account for the largest share of 44.3% of the ultrasound market. The large market share of this segment is attributed to the increasing number of hospitals & clinics, both in urban and rural areas, equipped with ultrasound machines for medical diagnostics. Furthermore, a significant portion of the population has resumed seeking healthcare services in the post-pandemic era, resulting in increased hospital visits for routine checkups and tests. This increase in demand contributes to the significant market share of this segment.

Among the regions covered in this report, in 2024, North America is expected to dominate the global ultrasound market with a share of 34.9%. North America’s major market share is attributed to patient awareness regarding early diagnosis, the well-established healthcare system in the U.S. and Canada, and the widespread adoption of advanced technologies.

Browse Sample Report Now- https://www.meticulousresearch.com/product/ultrasound-market-4972

Scope of the Report:

Ultrasound Market Assessment—by Component

Ultrasound DevicesTransducers/ProbesGelsOther Components

Note: The other components comprise probe racks, probe holders, disposable wipes, ultrasound needle guides, extender cables and adapters, and battery chargers & rechargeable batteries

Ultrasound Market Assessment—by Technology

Diagnostic Ultrasound2D Ultrasound3D and 4D UltrasoundDoppler UltrasoundColor Doppler ImagingContinuous Doppler ImagingPulse Wave Doppler ImagingTherapeutic UltrasoundHigh-Intensity Focused Ultrasound (HIFU)LithotripsyExtracorporeal Shock Wave Lithotripsy (ESWL)Shock Wave Lithotripsy (SWL)

Ultrasound Market Assessment—by Display

Colored DisplayBlack and White (B/W) Display

Ultrasound Market Assessment—by Portability

Cart/Trolley-based Ultrasound SystemsHandheld/Compact Ultrasound SystemsPoint of Care Ultrasound Systems

Ultrasound Market Assessment—by Application

Diagnostic ApplicationsGeneral ImagingCardiologyObstetrics/GynecologyVascularUrologyOther Diagnostic ApplicationsTherapeutic ApplicationsDrug DeliveryPhysical TherapyPain ManagementOther Therapeutic Applications

Note: Other diagnostic applications comprise abdominal and anesthesia.

Other therapeutic applications comprise thrombolysis and sonoporation.

Ultrasound Market Assessment—by End User

Hospitals and ClinicsDiagnostic Imaging CentersAmbulatory Care CentersAcademic and Research Institutes

Ultrasound Market Assessment—by Geography

North AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalySpainRest of Europe (RoE)Asia-PacificJapanChinaIndiaRest of APAC (RoAPAC)Latin AmericaBrazilMexicoRoLATAMMiddle East & Africa

Unlock Opportunities: Buy Now-
https://www.meticulousresearch.com/Checkout/30377746?utm_source=PRnewswire&utm_medium=Paid&utm_campaign=Product&utm_content=21-08-2024

Related Reports:

Portable Ultrasound Market by Product (POCUS, Handheld Ultrasound, Transducer, Gels), Technology (2D, 3D, 4D, Doppler), Display, Application (Breast Cancer, MSK, OB/GYN, CVD, Urology), End User (Hospitals, ACC, Imaging Center) – Global Forecast to 2031

Microbubbles/Ultrasound Contrast Agents Market by Application (Diagnostic Imaging [Cardiovascular, Renal, Abdominal, Breast] Therapeutics) Type (Lipid, Protein, Polymer) End User (Hospitals & Clinics, Diagnostics Laboratories) – Global Forecast to 2030

Ultrasound Transducers Market by Product (Convex, Linear, Endocavitary, Phased Array, CW Doppler), Application (Diagnostic [Cardiovascular, OB/GYN, Musculoskeletal), Therapeutic), End User (Hospitals, Diagnostic Centers, ASC) – Global Forecast to 2030

Veterinary Ultrasound Market by Animal Type [Small, Large (Equine, Farm)], Scanner [Cart-based, Handheld], Technology (2D, 3D/4D, Doppler), Application (Orthopedic, Cardiology, Obstetrics & Gynecology), End User (Clinic, Hospital) – Global Forecast to 2030

Artificial Intelligence in Medical Diagnostics Market by Component (Software, Services), Specialty (Radiology, Cardiology, Neurology, Obstetrics/Gynecology, Oncology), Modality (MRI, CT, X-ray, Ultrasound), End User (Hospital, Diagnostic Center) – Global Forecast to 2029

Medical Image Analysis Software Market by Software Type (Integrated, Standalone), Image (2D, 3D, 4D), Modality (X-ray, CT, Ultrasound, MRI), Application (Cardiology, Orthopedic, Neurology), End User (Hospital, Diagnostic Center)—Global Forecast to 2029

Diagnostic Imaging Market by Product (X-ray (Digital, Analog), MRI (Closed, Open), Ultrasound, CT, Nuclear Imaging (SPECT, PET), Application (Orthopedic, OB/GYN, MSK, Cardiology, Oncology), End User (Hospital, Imaging Centers) – Global Forecast to 2025

Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Meticulousblog.org | Top Market Research Reports Blog – https://meticulousblog.org/
Content Source: https://www.meticulousresearch.com/pressrelease/849/ultrasound-market-2031

Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/ultrasound-market-to-be-worth-18-07-billion-by-2031—exclusive-report-by-meticulous-research-302227536.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

ASUS Accelerates Enterprise AI at Scale with 6th-Gen AMD EPYC Server CPUs

Published

on

By

 ASUS leverages 6th-gen AMD EPYC Server CPUs to deliver scalable, efficient compute for enterprise AI, cloud, virtualization and business-critical workloads

SAN FRANCISCO, July 24, 2026 /PRNewswire/ — ASUS today announced its groundbreaking new server lineup powered by the AMD EPYC™ 9006 processors, engineered to deliver unmatched performance for the most demanding intensive enterprise workloads. This advanced portfolio introduces two highly optimized series with efficiency-optimized AMD EPYC SP8 server CPU, the flagship dual-socket ASUS RS700A/720A for extreme compute density and the single-socket ASUS RS500A/520A for superior space efficiency and deployment flexibility.

Both series integrate full PCIe® 6.0, leading memory support, and high-density E3.S storage, all underpinned by proprietary ASUS innovations for superior thermal management and operational efficiency to meet and exceed the rigorous demands of enterprise AI, virtualization, storage and cloud environments.

“The new ASUS server series, powered by 6th-gen AMD EPYC server CPUs, is engineered to power every enterprise workload with flexible, scalable infrastructure,” Paul Ju, Senior Vice President of ASUS, commented, “This launch marks a significant milestone for ASUS and our clients. The new series empowers businesses with a resilient foundation to achieve unprecedented computing efficiency and accelerating AI innovation with inference.”

ASUS expands 6th-gen AMD EPYC server portfolio with dual optimized series

ASUS has introduced a new server lineup segmented into two distinct series, each precisely engineered to meet diverse enterprise demands.

The flagship RS700A/720A series (dual-socket) delivers extreme compute density, making it ideal for AI inferencing, and complex simulations. It offers exceptional bandwidth with PCIe 6.0, memory leadership via 32 DIMM slots supporting ultrafast MRDIMM, and high-density storage with up to 32 E3.S bays in a compact 2U form factor.

Complementing this is the RS500A/520A series (single-socket), a highly efficient and space-optimized solution with depth under 800mm, perfect for mainstream enterprise workloads and rack-constrained environments. Featuring full PCIe 6.0 capabilities, E3.S storage support, and modular scalability through shared components with the RS700A and RS720A series, it provides uncompromised performance in a streamlined, deployment-friendly design.

ASUS elevates the AMD EPYC platform with cutting-edge proprietary innovations

ASUS has significantly advanced the AMD EPYC 9006 platform with a series of proprietary engineering breakthroughs focused on superior reliability, thermal management, and operational efficiency.

The DC-MHS modular architecture features a zone-partitioned chassis that separates I/O, HPM, fan, and storage modules to accelerate development, reduce capital costs, and enable rapid serviceability. The patented ASUS DIMM.2 Innovation repositions M.2 storage to the cooler DIMM region, eliminating thermal throttling without extra heatsinks and unlocking greater scalability. Thermal Radar 3.0 with PID Control delivers precise real-time fan regulation via advanced algorithms, reducing energy use and maintaining peak performance under heavy enterprise-level workload.

Completing the suite is the optimized tool-less operational-velocity design, which boosts maintenance efficiency, maximizing uptime and lowering TCO and sustaining peak performance even under volatile, high-load AI/HPC workloads.

AVAILABILITY & PRICING

ASUS RS700A/720A series and RS500A/520A series servers will be available soon. Please contact your local ASUS representative for further information.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/asus-accelerates-enterprise-ai-at-scale-with-6th-gen-amd-epyc-server-cpus-302833931.html

Continue Reading

Technology

Fractal posts 20% revenue growth and 92% net income growth in Q1 FY27

Published

on

By

Adjusted EBITDA Grows at 35% YoYGross Margin up 29 bps1 to 46%; Adjusted EBITDA Margin up 189 bps to 17%

NEW YORK, July 24, 2026 /PRNewswire/ — Fractal Analytics Ltd (BSE: 544700) (NSE: FRACTAL) announced its consolidated financial results for Q1 FY27, ending June 30, 2026.

In Q1 FY27, the Company reported consolidated operating revenue of INR 9,125 m, a growth of 20% year on year (YoY). Revenue growth was led by the company’s Healthcare and Life Sciences (HLS) industry, which clocked 69% growth YoY. Strong sustained growth in HLS over the last several quarters has resulted in it becoming the second largest industry in the portfolio. Banking, Financial Services and Insurance (BFSI) also performed very well, growing 36% YoY in Q1. Fractal’s largest industry, Consumer Packaged Goods and Retail (CPGR), continued to gather momentum, growing 19% YoY. On the other hand, TMT declined 22% YoY.

Fractal’s focus on deepening customer relationships continues to yield good outcomes. Its clients collectively increased their spending with the company, as reflected in the Net Revenue Retention2 of 117% in Q1. Further, its Net Promoter Score (NPS) during the period stood at 77.

The company reported improved profit margins at all levels. Gross Margin in Q1 was at 46%, while Adjusted EBITDA Margin expanded by 189 bps YoY to 17%. Net Income grew 92% YoY to INR 723 m.

Commenting on the performance, Srikanth Velamakanni, Group CEO and Executive Vice-Chairman, said:

“Enterprises are putting real transformation budgets behind AI now and we’re seeing it directly in the size of the deals coming to us. TMT was the drag on our headline growth this quarter. Excluding TMT, our business grew 35% year on year, which is a better read on the underlying demand we’re seeing.

As data sovereignty becomes a bigger priority for governments and enterprises, and as open-weight models keep improving, clients need a partner who can work across models and infrastructure. We have invested heavily in our people, our research, and our own intellectual property to be that partner.”

1 Basis points = 1/100th of 1%
2 Net Revenue Retention in our Fractal.ai segment measures how effectively we retain and expand revenue from our existing clients over a defined period and is calculated by comparing the current period’s revenue from the clients who existed at the start of the period, with their revenue in the previous period – including the effects of upsells, cross-sells and contractions

About Fractal 

Fractal Analytics Ltd (BSE: 544700) (NSE: FRACTAL) is a globally recognized pure-play enterprise AI company trusted by Fortune 500®-sized enterprises to power decision-making through AI services, solutions, and products, anchored by Cogentiq, its flagship agentic AI platform. With over 6,000 professionals across North America, EMEA, and Asia-Pacific, Fractal partners with business leaders to drive competitive differentiation for their organizations by embedding AI into critical decisions across business functions and industry verticals.

Fractal invests more than 6% of its revenue in AI R&D, supporting foundational AI research, product development, and IP creation that address both immediate client needs and long-term technological advancement. Fractal’s track record includes developing proprietary models and products such as Cogentiq Health – Vaidya.ai and Cogentiq Data Science – PiEvolve, as well as incubating and spinning out Qure.ai, a global healthcare AI leader focused on the rapid identification and management of tuberculosis, lung cancer, and stroke (or critical health conditions). Fractal’s suite of businesses consists of Asper.ai (a Revenue Growth Management product for CPG companies) and Analytics Vidhya (an Ed-tech platform).

For more information, go to www.fractal.ai.

Logo: https://mma.prnewswire.com/media/2931510/5858548/Fractal_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/fractal-posts-20-revenue-growth-and-92-net-income-growth-in-q1-fy27-302833932.html

SOURCE Fractal Analytics Limited

Continue Reading

Technology

Xryma Plc : Pre-Listing Liquidity Facility and Price Discovery Process

Published

on

By

NICOSIA, Cyprus, July 24, 2026 /PRNewswire/ — Xryma Plc (“Xryma”)  announces its intention to reapply within the next twelve months for admission to list on Euronext Paris (“Euronext”), with such admission being subject to Euronext’s approval. Before submitting its application, Xryma intends to launch a pre-listing liquidity facility and price discovery process, comprising a private placement to institutional and qualified investors alongside a secondary market offer to Xryma existing shareholders (“shareholders”) wishing to exit prior to listing.  

The admission referred to above that is subject to the approval of Euronext may also be subject to approval by relevant regulatory authorities, and no assurance can be given that approval will be granted or as to the timing of any admission.

The pre-listing liquidity facility and price discovery process is designed to:

Enable shareholders seeking an exit to participate without the need to open an EU brokerage account,Provide a clear and orderly opportunity for existing shareholders to sell all or part of their holdings ahead of any potential admission to trading on Euronext Paris,Enable shareholders to sell all or part of their holdings at the same price at which qualified and institutional investors subscribe for shares in the Company,Establish, through a bookbuild with qualified and institutional investors, a market-validated referenced price for Xryma shares ahead of any potential admission on Euronext Paris (the “Primary Market Placement Price”),Support orderly trading upon potential admission.

Individual shareholder mailouts explaining the details of the pre-listing liquidity facility scheme with instructions and necessary documentation will be conducted during August 2026.

As the Primary Market Placement Price is to be determined by the subsequent bookbuild, shareholders will be given the opportunity to set a floor price which will result in the sale of their shares if the Primary Market Placement Price is higher.  Shareholders will receive the Primary Market Placement Price minus applicable fees.

Shareholders and Investors may be scaled back to match corresponding demand from the other party, with partial fulfilment a possibility if the Company cannot match supply to demand.

Completion of the process is subject to achieving a level of institutional and qualified investor demand that the Board considers appropriate to support an orderly market should Xryma subsequently be admitted to trading on Euronext Paris.

Participation is entirely voluntary. Shareholders who do not wish to sell will simply retain their shares. Shareholders that do not intend to participate should continue to onboard with a Euronext participating broker, or a Euroclear ESES custodian, per previous communications.

The major shareholders, SCP Select All Enterprise (Monaco) and SCP Red 5 Solutions (Monaco) will not participate in the offer and will be subject to lock up arrangements.

Mr Nikogiannis (John) Karantzis, CEO of Xryma Plc comments: “Our shareholders have told us they would value a straightforward way to realise their holdings without the time and cost of opening an EU brokerage account. This process is our response to that feedback. We are structuring the placement to be large enough to establish a credible reference price whilst limiting dilution, with demand directed first towards meeting shareholder sell interest. We look forward to updating the market on the revised timetable in due course.”

Shareholders seeking a more detailed explanation of the pre-listing liquidity facility and price discovery process, should refer to the guide available at https://www.xryma.com/investors

Important Information & Disclaimers

This press release may contain inside information within the meaning of Article 7(1) of Regulation (EU) 596/2014 (Market Abuse Regulation).

This publication is not for publication or distribution or release, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Canada, Australia, South Africa, Japan or any other jurisdiction where such an announcement would be unlawful. The distribution of this publication may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. No action has been taken that would permit an offering of the treasury shares or possession or distribution of this publication in any jurisdiction where action for that purpose is required.

This publication does not constitute or form part of an offer for sale or solicitation of an offer to purchase or subscribe for securities in the United States, Canada, Australia, South Africa, Japan or any other jurisdiction and the securities referred to herein have not been registered under the securities laws of any such jurisdiction. Any New Shares (if such are issued) will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any State or any other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of, the Securities Act and in compliance with all applicable securities laws of any State or any other jurisdiction of the United States. No public offering of securities is being made in the United States or in any other jurisdiction.

The information set forth herein must not be distributed in any jurisdiction where such distribution is unlawful, and any recipients are requested to inform themselves about and to observe such restrictions.

The Offering referred to herein by Xryma Plc will only be made in accordance with all applicable corporate and securities laws. Any shares referred to herein will exclusively be offered or sold in reliance on any applicable exemptions from prospectus or registration requirements in any jurisdiction. In member states of the European Economic Area, this publication is only addressed to and directed at persons who are ‘qualified investors’ within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (as amended and including any relevant delegated regulations, the “Prospectus Regulation”) or in any other circumstances falling within exemptions available in the relevant member state under Article 1(4) and/or 1(5) of the Prospectus Regulation. In the United Kingdom, this publication is only addressed to and directed at qualified investors within the meaning of the Prospectus Regulation, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (“EUWA”), who are persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Order”), (ii) falling within article 49(2)(a) to (d) (high net worth companies, incorporated associations, etc.) of the Order, or (iii) to whom it may otherwise be lawfully communicated; any other persons in the United Kingdom should not take any action on the basis of this publication and should not act on or rely on it.

This publication does not constitute a recommendation concerning the prospective Offering. This announcement does not constitute an Offer or invitation to subscribe.

This announcement includes statements that are, or may be deemed to be, ‘forward looking statements’. These forward-looking statements can be identified by the use of forward looking terminology, including the terms ‘believes’, ‘estimates’, ‘anticipates’, ‘expects’, ‘intends’, ‘may’, ‘will’, or ‘should’ or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances which may or may not occur. Many of these factors are beyond the control of the Company. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results and circumstances may vary materially from those described in this announcement as anticipated, believed, estimated or expected.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/xryma-plc–pre-listing-liquidity-facility-and-price-discovery-process-302833658.html

Continue Reading

Trending